The Netherlands’ R&D agency TNO has launched a digital health company – AIKON Health – that will focus on the development of wearable devices that will be used to moni
Astellas has licensed rights to a smart stethoscope device developed by Eko Health, that it will use as part of a digital therapeutic (DTx) approach to heart failure.
Lexicon Pharma tried and failed to get FDA approval for its SGLT inhibitor sotagliflozin for diabetes, but it has finally got the drug over the finish line – for a differe
The FDA has approved AstraZeneca’s SGLT2 inhibitor Farxiga as a treatment candidate for all patients with heart failure, putting the drug back in contention with rival Jar
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.